JUST IN: Limited-Time Access to Full Transcript of Our Urgent Broadcast on India's Revival
Here is the latest financial fact sheet of STRIDES PHARMA SCIENCE. For more details, see the STRIDES PHARMA SCIENCE quarterly results and STRIDES PHARMA SCIENCE share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 7.8 |
No. of shares | m | 59.65 |
% ch week | % | 8.8 |
% ch 1-mth | % | 9.1 |
% ch 12-mth | % | 173.1 |
52 week H/L | Rs | 1,000.0/322.0 |
No. of Mths Year Ending |
15 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
---|
STRIDES PHARMA SCIENCE EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,138 | 1,199 | 1,413 | 1,275 | 1,147 | |
Low | Rs | 344 | 384 | 848 | 918 | 642 | |
Sales per share (Unadj.) | Rs | 225.1 | 200.6 | 320.3 | 308.1 | 317.2 | |
Earnings per share (Unadj.) | Rs | 296.6 | 141.7 | 13.2 | 31.3 | 7.8 | |
Diluted earnings per share | Rs | 296.2 | 141.7 | 19.8 | 46.9 | 11.8 | |
Cash flow per share (Unadj.) | Rs | 306.1 | 152.5 | 27.9 | 45.4 | 25.1 | |
Dividends per share (Unadj.) | Rs | 505.00 | 108.00 | 5.00 | 4.50 | 2.00 | |
Adj. dividends per share | Rs | 504.32 | 107.95 | 7.49 | 6.75 | 3.00 | |
Dividend yield (eoy) | % | 68.2 | 13.7 | 0.4 | 0.4 | 0.2 | |
Book value per share (Unadj.) | Rs | 169.0 | 193.9 | 297.5 | 307.4 | 274.3 | |
Adj. book value per share | Rs | 168.8 | 193.8 | 445.6 | 460.8 | 411.5 | |
Shares outstanding (eoy) | m | 59.57 | 59.62 | 89.35 | 89.42 | 89.50 | |
Bonus/Rights/Conversions | ESOP | ESOP | ESOP | ESOP | ESOP | ||
Price / Sales ratio | x | 3.3 | 3.9 | 3.5 | 3.6 | 2.8 | |
Avg P/E ratio | x | 2.5 | 5.6 | 85.5 | 35.1 | 114.0 | |
P/CF ratio (eoy) | x | 2.4 | 5.2 | 40.5 | 24.2 | 35.7 | |
Price / Book Value ratio | x | 4.4 | 4.1 | 3.8 | 3.6 | 3.3 | |
Dividend payout | % | 170.3 | 76.2 | 37.8 | 14.4 | 25.5 | |
Avg Mkt Cap | Rs m | 44,135 | 47,165 | 100,988 | 98,036 | 80,058 | |
No. of employees | `000 | 1.5 | 2.0 | 4.7 | 5.8 | 2.5 | |
Total wages/salary | Rs m | 1,572 | 1,721 | 3,577 | 4,192 | 4,341 | |
Avg. sales/employee | Rs Th | 8,939.5 | 5,979.3 | 6,102.8 | 4,750.8 | 11,325.8 | |
Avg. wages/employee | Rs Th | 1,047.9 | 860.3 | 762.7 | 722.7 | 1,731.4 | |
Avg. net profit/employee | Rs Th | 11,778.3 | 4,225.0 | 251.9 | 482.2 | 280.1 |
STRIDES PHARMA SCIENCE INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 13,409 | 11,959 | 28,622 | 27,554 | 28,394 | |
Other income | Rs m | 602 | 386 | 921 | 1,611 | 941 | |
Total revenues | Rs m | 14,012 | 12,344 | 29,543 | 29,165 | 29,334 | |
Gross profit | Rs m | 2,234 | 2,289 | 4,140 | 5,274 | 3,965 | |
Depreciation | Rs m | 565 | 640 | 1,313 | 1,262 | 1,540 | |
Interest | Rs m | 1,089 | 474 | 1,682 | 1,831 | 1,962 | |
Profit before tax | Rs m | 1,183 | 1,560 | 2,067 | 3,792 | 1,403 | |
Minority Interest | Rs m | -6 | 6 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | -47 | 4 | -168 | |
Extraordinary Inc (Exp) | Rs m | 19,736 | 8,361 | -414 | -364 | -436 | |
Tax | Rs m | 3,245 | 1,476 | 425 | 634 | 97 | |
Profit after tax | Rs m | 17,667 | 8,450 | 1,181 | 2,797 | 702 | |
Gross profit margin | % | 16.7 | 19.1 | 14.5 | 19.1 | 14.0 | |
Effective tax rate | % | 274.3 | 94.6 | 20.5 | 16.7 | 6.9 | |
Net profit margin | % | 131.8 | 70.7 | 4.1 | 10.2 | 2.5 |
STRIDES PHARMA SCIENCE BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 13,086 | 14,447 | 35,149 | 37,918 | 24,836 | |
Current liabilities | Rs m | 7,074 | 10,022 | 18,920 | 31,039 | 18,993 | |
Net working cap to sales | % | 44.8 | 37.0 | 56.7 | 25.0 | 20.6 | |
Current ratio | x | 1.8 | 1.4 | 1.9 | 1.2 | 1.3 | |
Inventory Days | Days | 48 | 63 | 78 | 97 | 71 | |
Debtors Days | Days | 99 | 112 | 132 | 132 | 113 | |
Net fixed assets | Rs m | 5,506 | 8,400 | 35,682 | 37,639 | 34,289 | |
Share capital | Rs m | 596 | 596 | 894 | 894 | 895 | |
"Free" reserves | Rs m | 4,594 | 10,962 | 25,685 | 26,594 | 23,651 | |
Net worth | Rs m | 10,068 | 11,558 | 26,579 | 27,488 | 24,546 | |
Long term debt | Rs m | 2,755 | 2,530 | 26,270 | 16,377 | 15,513 | |
Total assets | Rs m | 20,990 | 24,805 | 74,559 | 81,050 | 65,437 | |
Interest coverage | x | 2.1 | 4.3 | 2.2 | 3.1 | 1.7 | |
Debt to equity ratio | x | 0.3 | 0.2 | 1.0 | 0.6 | 0.6 | |
Sales to assets ratio | x | 0.6 | 0.5 | 0.4 | 0.3 | 0.4 | |
Return on assets | % | 89.4 | 36.0 | 3.8 | 5.7 | 4.1 | |
Return on equity | % | 175.5 | 73.1 | 4.4 | 10.2 | 2.9 | |
Return on capital | % | 171.6 | 73.8 | 6.2 | 12.0 | 6.9 | |
Exports to sales | % | 59.4 | 60.2 | 53.1 | 0 | 0 | |
Imports to sales | % | 20.5 | 23.5 | 15.9 | 0 | 0 | |
Exports (fob) | Rs m | 7,959 | 7,204 | 15,192 | 0 | 0 | |
Imports (cif) | Rs m | 2,752 | 2,809 | 4,565 | 0 | 0 | |
Fx inflow | Rs m | 22,791 | 13,031 | 16,612 | 13,465 | 15,697 | |
Fx outflow | Rs m | 3,088 | 3,165 | 5,292 | 4,076 | 735 | |
Net fx | Rs m | 19,703 | 9,865 | 11,320 | 9,389 | 14,962 |
STRIDES PHARMA SCIENCE CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -2,717 | 834 | 733 | 2,881 | 1,871 | |
From Investments | Rs m | 40,771 | 519 | -22,248 | -6,867 | 5,826 | |
From Financial Activity | Rs m | -33,185 | -4,213 | 29,439 | 3,382 | -10,157 | |
Net Cashflow | Rs m | 4,869 | -2,860 | 7,924 | -603 | -2,615 |
Share Holding
|
Company Information
|
CHM: Deepak Vaidya (MD) | COMP SEC: Badree Komandur (EVP-Finance) | YEAR OF INC: 1980 | BSE CODE: 532531 | FV (Rs): 10 | DIV YIELD (%): 0.3 |
Read: STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: FDC DISHMAN PHARMA ALEMBIC INDRAPRASTHA MEDICAL DIVIS LABORATORIES
Compare STRIDES PHARMA SCIENCE With: FDC DISHMAN PHARMA ALEMBIC INDRAPRASTHA MEDICAL DIVIS LABORATORIES
Compare STRIDES PHARMA SCIENCE With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More